HASANFLON 500 mg is an oral phlebotropic drug indicated in the treatment of venous disease, ie, chronic venous disease (CVD) and hemorrhoidal disease (HD).
HASANFLON 500 mg is a unique micronized purified flavonoid fraction (MPFF) containing 90% diosmin (450 mg) and 10% flavonoids (50 mg) expressed as Hesperidin.
The unique active substance of HASANFLON 500 mg is composed of diosmin and active concomitant flavonoid substances: hesperidin, isorhoifolin, linarin and diosmetin.
Hesperidin is extracted from a species of Rutaceae aurantieae, a type of immature small orange harvested and dried in Spain, North Africa, and China. Diosmin, a member of the flavonoid family, is synthesized starting from this raw material.1,2
HASANFLON 500 mg differs from ordinary diosmins by its unique composition in flavonoids3 and the unique micronization of its active substance.4
Micronization means that the active ingredient of HASANFLON 500 mg undergoes a high-tech grinding process with a jet of air at supersonic velocities, reducing the size of standard particles from 37 µm to less than 2 µm. Thanks to its unique micronized form, HASANFLON 500 mg has better and faster absorption, and thus an increased bioavailability of its active substance, which leads to faster and superior clinical efficacy in both indications, chronic venous disease and hemorrhoidal disease by at least 30% over nonmicronized ordinary diosmins.4-8
HASANFLON 500 mg has a unique and rigorously demonstrated mode of action, which enables it to fight simultaneously all the pathophysiological aspects of venous disease, affecting the veins, lymphatics, and microcirculation.
HASANFLON 500 mg prolongs the vasoconstrictor effect of noradrenaline on the vein wall, even under warm and acidotic conditions, increasing venous tone, and therefore reducing venous capacitance, distensibility, and stasis. This increases the venous return and reduces venous hyperpressure present in patients suffering from chronic venous disease.
At the macrocirculatory level, HASANDAFLON 500 mg has been recently proven to protect the venous valves from leukocyte-induced inflammation and destruction, preventing the appearance of reflux, and therefore protecting against the progression of chronic venous disease toward complications.9-11
HASANFLON 500 mg improves lymphatic drainage by increasing the frequency and intensity of lymphatic contractions, and by increasing the total number of functional lymphatic capillaries. Furthermore, HASANFLON 500 mg decreases the diameter of lymphatic capillaries and the intralymphatic pressure.12,13
At the microcirculation level, HASANFLON 500 mg reduces capillary hyperpermeability and increases capillary resistance by protecting the microcirculation from inflammatory damaging processes. HASANFLON 500 mg reduces the expression of adhesion molecules on endothelial cells (ICAM1, VCAM1)14 and on leukocytes (L-selectin, VLA-4, CD 11b),8 and inhibits the adhesion, migration, and activation of leukocytes at the capillary level. This leads to a reduction in the release of inflammatory mediators, principally oxygen free radicals and prostaglandins (PGE2, PGF2a).15-22
This protective and reinforcing action on the venous and lymphatic system, associated with the vasculoprotective effect on the macro- and the microcirculation, explains the restorative and protective efficacy of HASANFLON 500 mg in chronic venous disease and hemorrhoidal disease, both of which are associated with perivascular inflammation and edema.
In patients suffering of chronic venous disease, HASANFLON 500 mg provides significant relief from all disabling symptoms,7,22-27 such as pain, heavy legs, cramps, and sensation of swelling. Moreover, HASANFLON 500 mg also significantly improves clinical signs, such as leg edema,24,25 skin disorders,28 and venous leg ulcer.29-31
This improvement of signs and symptoms contributes to a significant increase in patients' quality of life, as assessed with a validated international scale specific to chronic venous disease: the CIVIQ questionnaire.24
1. Venous leg ulcer
In venous ulcer, HASANFLON 500 mg, 2 tablets daily is an effective adjunct to conventional therapy (compression and local care) that increases the chance of healing leg ulcer by at least 32% at 6 months, and shortens ulcer healing time by 5 weeks.
Large and long-standing ulcers (>5 cm² and >6 months) are found to benefit most from adjunctive therapy with HASANFLON 500 mg, these ulcers being slow and more difficult to heal.29-31
2. Postsurgical and postradiotherapy lymphedema
Administration of HASANFLON 500 mg, 2 tablets daily, for 6 months in patients who had lymphedema after breast cancer surgery leads to a 1.5% to 13.4% decrease in circumference of the affected arm, an improvement in tissue elasticity, and an improvement in lymphatic drainage functional parameters, evaluated by isotope scan.32 Another double-blind, placebo controlled study, with an equal treatment period and dosage, demonstrated that HASANFLON 500 mg induces and increases the velocity of lymphatic drainage on isotope scan, improves functional disturbances, and constantly decreases the volume of the affected arm.33
In acute hemorrhoidal attacks, HASANFLON 500 mg is highly effective, right from the second day of treatment, in improving all signs and symptoms, such as bleeding, pain, discharge, tenesmus, and proctitis, thereby reducing the consumption of oral analgesics.34-36
The efficacy of HASANFLON 500 mg associated with fiber supplement has been superior to fiber supplement alone and equivalent to rubber-band ligation plus fiber supplement in stopping anal bleeding due to hemorrhoids.37
HASANFLON 500 mg combined with an infrared photocoagulation technique (IRP) is more effective in rapidly stopping bleeding than IRP alone.38
HASANFLON 500 mg combined with hemorrhoidectomy significantly reduces the risk of postoperative bleeding and reduces the postoperative healing time.39,40
In long-term treatment for chronic hemorrhoidal disease, HASANFLON 500 mg has been proven to significantly reduce recurrence, duration, number, and severity of hemorrhoidal attacks.35,41
- Chronic venous disease: 2 tablets daily
- Hemorrhoidal disease:
Hemorrhoidal attacks: 6 tablets daily for 4 days followed by 4 tablets daily for 3 days
Chronic hemorrhoids: 2 tablets daily